Effect of canrenone and amiloride on the prooxidative effect induced by aldosterone in human mononuclear leukocytes in vitro.
Clinical studies have demonstrated that aldosterone receptor antagonists do improve the survival of patients with chronic heart diseases and in vitro studies have shown that canrenone blocks the proinflammatory effect of aldosterone in mononucler leukocytes (MNL). The aim of the study was to compare, in the model of human MNL, the effect of potassium-sparing diuretics amiloride and canrenone, on the protein expression of p22phox, a NADPH-oxidase system subunit, that is a principal marker of production of superoxide anions. MNL were isolated from 10 informed healthy volunteers (5 males and 5 females, age range 24-36 yr) and the proteins extracted. p22phox protein expression was evaluated by Western blot and quantified using a densitometric semiquantitative analysis. The experiments showed that aldosterone (10(-8) M) enhances the protein expression of p22phox and that its effect is reversed by co-incubation with canrenone (10(-6) M), while incubation with amiloride (10(-6) M) reduced the prooxidative effect of aldosterone at a significantly lower extent than canrenone. Co-incubation with canrenone, amiloride, and aldosterone together produced the same effect as aldosterone plus canrenone. Incubation with cortisol (40(-8) M) was not effective. These data confirm the prooxidative effect of aldosterone in MNL. The addition of aldosterone-receptor antagonist canrenone produced a higher inhibition than sodium channel blocker amiloride on the effect of aldosterone on p22phox protein expression.
Fiore
C
C
Department of Medical and Surgical Sciences, Endocrinology, University of Padua, Via Ospedale 105, 35100 Padua, Italy.
Sartorato
P
P
Pagnin
E
E
Ragazzi
E
E
Calò
L A
LA
Armanini
D
D
D000328:Adult; D000450:Aldosterone / Q000494:pharmacology*; D000584:Amiloride / Q000494:pharmacology*; D002192:Canrenone / Q000494:pharmacology*; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000494:pharmacology; D007963:Leukocytes, Mononuclear / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D000451:Mineralocorticoid Receptor Antagonists / Q000494:pharmacology; D019255:NADPH Oxidases / Q000096:biosynthesis* / Q000187:drug effects; D026941:Sodium Channel Blockers / Q000494:pharmacology
D000451:Mineralocorticoid Receptor Antagonists; D026941:Sodium Channel Blockers; D000450:Aldosterone; D002192:Canrenone; D000584:Amiloride; D019255:NADPH Oxidases; C086986:CYBA protein, human; D006854:Hydrocortisone